跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
REXULTI - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
REXULTI
Authorized
STANDARD
REXULTI
OTSUKA PHARMACEUTICAL CO., LTD.
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f3c2f3c3a6f76459
Company
OTSUKA PHARMACEUTICAL CO., LTD.
Type
Standard
Approval Details
Approval Id
f3c2f3c3a6f76459
Drug Approval Canada Name
REXULTI
Product Name
REXULTI
Status
Cancelled Post Market
Status Date
2022-10-31
Original Market Date
2019-06-08
Din
02485923
Drug Class
Human
Dosage Form
Kit , Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
28:16.08.04
Atc Original
N05AX16 BREXPIPRAZOLE
Atc Name
n 05 ax 16
Aig Number
0261230001
Company Name
OTSUKA PHARMACEUTICAL CO., LTD.
Company Address
2-9 Kanda-Tsukasamachi, Chiyoda-Ku Tokyo, --, Japan, 101-8535
Company Detail Path
/organization/otsuka-pharmaceutical-co-ltd
Company Information
Pharmaceutical Company Name
OTSUKA PHARMACEUTICAL CO., LTD.
Country Name
Japan
Province Name
Tokyo
City Name
minato-ku,tokyo,country_jp
Address
2-16-4, KONAN
Website
http://www.otsuka.co.jp
Active Ingredients
BREXPIPRAZOLE
1 MG
BREXPIPRAZOLE
0.5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f3c2f3c3a6f76459
Type
Standard
Back to Health Canada Approvals